Literature DB >> 15838931

A molecular model to explain paclitaxel and docetaxel sensitivity changes through adduct formation with primary amines in electrospray ionization mass spectrometry.

Sunil S Iyer1, Songmei Gao, Zong-Ping Zhang, Glen E Kellogg, H Thomas Karnes.   

Abstract

The objective of this study was to adopt a molecular modeling approach to understand changes in signal intensity due to adduct formation with short-chain alkylamines for two anticancer agents, paclitaxel and docetaxel, during electrospray mass spectrometric analysis. We describe a simple and intuitive modeling procedure using a comparison of hydropathic interaction (HINT) scores to explain differences in responses of amine adducts formed with the two analytes. The responses of paclitaxel and docetaxel were generally enhanced considerably (up to approximately 500% in some instances) on adding the amines. However, for the docetaxel adduct formed with added decylamine in the mobile phase, the response dropped by 32%. A mechanistic understanding for this behavior is proposed, and binding scores calculated from corresponding molecular models were found to be consistent with the trend obtained from mass spectrometric data. Copyright 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15838931     DOI: 10.1002/rcm.1914

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  2 in total

1.  Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.

Authors:  Alina Shapira; Yehuda G Assaraf; Dikla Epstein; Yoav D Livney
Journal:  Pharm Res       Date:  2010-08-12       Impact factor: 4.200

2.  β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.

Authors:  Maya Bar-Zeev; Yehuda G Assaraf; Yoav D Livney
Journal:  Oncotarget       Date:  2016-04-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.